Hanmi Pharm Co Ltd
KRX:128940

Watchlist Manager
Hanmi Pharm Co Ltd Logo
Hanmi Pharm Co Ltd
KRX:128940
Watchlist
Price: 267 500 KRW 0.38%
Market Cap: 3.4T KRW
Have any thoughts about
Hanmi Pharm Co Ltd?
Write Note

Hanmi Pharm Co Ltd
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Hanmi Pharm Co Ltd
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Hanmi Pharm Co Ltd
KRX:128940
Accrued Liabilities
â‚©52.7B
CAGR 3-Years
23%
CAGR 5-Years
11%
CAGR 10-Years
15%
Yuhan Corp
KRX:000100
Accrued Liabilities
â‚©37.5B
CAGR 3-Years
213%
CAGR 5-Years
36%
CAGR 10-Years
48%
SK Biopharmaceuticals Co Ltd
KRX:326030
Accrued Liabilities
â‚©71.3B
CAGR 3-Years
25%
CAGR 5-Years
24%
CAGR 10-Years
N/A
Hanmi Science Co Ltd
KRX:008930
Accrued Liabilities
â‚©10.4B
CAGR 3-Years
17%
CAGR 5-Years
18%
CAGR 10-Years
12%
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Accrued Liabilities
â‚©10.9B
CAGR 3-Years
9%
CAGR 5-Years
5%
CAGR 10-Years
14%
C
Celltrion Pharm Inc
KOSDAQ:068760
Accrued Liabilities
â‚©313m
CAGR 3-Years
-47%
CAGR 5-Years
-26%
CAGR 10-Years
-17%
No Stocks Found

Hanmi Pharm Co Ltd
Glance View

Market Cap
3.4T KRW
Industry
Pharmaceuticals

Hanmi Pharm Co., Ltd. is a remarkable player in the pharmaceutical industry hailing from South Korea, a country renowned for its technological and medical advancements. The company's journey began in 1973, and it has since carved out a substantial niche within the pharma sector by focusing on innovative research and development. Hanmi Pharm has been particularly recognized for its strong pipeline in pharmaceuticals addressing diabetes, oncology, and autoimmune diseases. It leverages its cutting-edge proprietary technology platforms such as LAPSCOVERY, which is dedicated to creating long-acting biologics, and Quantum Project, focused on novel small molecule drugs. These platforms are pivotal to Hanmi's strategy, enabling it not only to excel in creating new drugs but also to foster partnerships and licensing deals on a global scale, which constitute a significant revenue stream for the company. Beyond innovation, Hanmi Pharm has diversified its business operations across various sectors of pharmaceuticals including finished goods, active pharmaceutical ingredients (APIs), and over-the-counter (OTC) products. The company's revenue model is multifaceted and robust; it generates income by selling its pharmaceuticals in domestic and international markets and taps into significant contract manufacturing opportunities. Additionally, Hanmi Pharm has managed to establish strategic alliances with global pharmaceutical giants, resulting in lucrative licensing agreements. These collaborations allow Hanmi to not only broaden its distribution channels but also enhance its R&D capabilities by synergizing with the technological prowess of its partners. Through these multifarious routes, Hanmi Pharm has built a complex, enduring, and well-oiled machine that propels its financial growth and sustains its competitive edge within the industry.

Intrinsic Value
373 830.22 KRW
Undervaluation 28%
Intrinsic Value
Price

See Also

What is Hanmi Pharm Co Ltd's Accrued Liabilities?
Accrued Liabilities
52.7B KRW

Based on the financial report for Sep 30, 2024, Hanmi Pharm Co Ltd's Accrued Liabilities amounts to 52.7B KRW.

What is Hanmi Pharm Co Ltd's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
15%

Over the last year, the Accrued Liabilities growth was 4%. The average annual Accrued Liabilities growth rates for Hanmi Pharm Co Ltd have been 23% over the past three years , 11% over the past five years , and 15% over the past ten years .

Back to Top